Mid career · publishing since 2012Rising activity
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer, Hypoxia, and MetabolismMedical Imaging Techniques and ApplicationsCytokine Signaling Pathways and Interactions
Publications
66
Citations
943
Est. group size
~5
Recurring co-author estimate
Active years
15
Publishing since 2012
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 943p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 8.4p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~18 · 2% small-team papers (≤3 authors) · across 11 venues
Publication cadence
Publications per year over the last 10 years — averaging 8.4/year recently
Recent publications
- Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Table 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Figure 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Table 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023
- Table S2 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023
- Table S5 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023
- Table S4 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023
- Table S3 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023
- Table S1 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023
- Supplemental Materials and Methods from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023
Publishes in
- The Journal of Immunology×2
- Science×1
- Cell Death and Disease×1
- eLife×1
- Immunological Reviews×1
Similar researchers
By research-topic overlap
- Mukesh K. Nyati
Medicine · University of Michigan
- Tamio Okimoto
Medicine · The Ohio State University
- Jaimin K. Rana
Medicine · University of Michigan
- Xueding Wang
Medicine · University of Michigan
- Yina Wang
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile